Based on our patent-pending class of ionizable lipids, and novel core-lipid construct, we can design LNP-formulations for various types of applications. We have lipids available that are suitable for vaccination by delivering an adjuvating signal, as well as lipids with very low immunogenicity for therapy development.
However, we are not restricted to using our proprietary lipids. We also have extensive experience with formulating mRNA with commercially available lipids and experimental customer-generated lipids.
Working together with the targeting experts at mRNA drug-developer Mercurna, we offer tissue- or cell-specific targeting modifications of the LNP. A limited number of peptide-based targeting moieties is already available and via co-development novel targeting peptides may be developed. Non-peptide targeting ligands such as antibodies, DARPINs, glycans and others are also possible, because we have a variety of click chemistries available.